secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2024-06-28T23:59:59+00:00
Accession:  0001193125-24-172277
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica amends credit agreement with OrbiMed; revenue test deferred to Sept 30, 2024
--------------------------------------------------------------------------------

- Amendment to Credit Agreement moves revenue test start from earlier date to September 30, 2024.
- $500,000 amendment fee paid to lenders in connection with the amendment.
- Revenue test determines if principal payments (including premium) are required based on YCANTH net revenue.
- No other terms of the Credit Agreement were changed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524172277/0001193125-24-172277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524172277/d844833d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-172277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer